

## COMPANY OVERVIEW

Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. Citius is currently advancing two proprietary product candidates, our Mino-Lok™ product and a hydrocortisone-lidocaine formulation. Citius believes the markets for its products are large and underserved by the current standard of care.

## RECENT NEWS

### Citius Pharmaceuticals Successfully Raises \$5.3 Million

Apr 4 2019, 8:30 AM EDT

### Citius Announces \$5.3 Million Registered Direct Offering Priced At-the-Market

Apr 1 2019, 9:00 AM EDT

### Citius Pharmaceuticals to Present at NobleCon15 Investor Conference

Jan 25 2019, 8:00 AM EST

## STOCK OVERVIEW

Symbol	CTXR
Exchange	Nasdaq
Market Cap	23.4m
Last Price	\$1.06
52-Week Range	\$0.8582 - \$3.15

04/25/2019 04:00 PM EDT

## INVESTOR RELATIONS

Andrew Scott  
VP of Investor Relations  
T: 908-967-6677 ext. 105

## MANAGEMENT TEAM

### Myron Holubiak

President, Chief Executive Officer and Director

### Jaime Bartushak

Chief Financial Officer and Principal Financial Officer

### Gary F. Talarico

Executive Vice President, Operations

## CITIUS PHARMACEUTICALS, INC.

11 Commerce Drive, First Floor  
Cranford, NJ 07016  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.